Triple Analysis: Antibody Drug Target Atlas in Oncology and Special Focus on Melanoma and NSCLC

Table of Contents

1 Executive Summary

2 Methodologies

3 Table of Contents

• 3.1 List of Figures
• 3.2 List of Tables
• 3.3 List of Boxes

4 Antibody Drug Target Analysis in Oncology: What and Where Are We Targeting?

5 Antibody Drug Targets by Molecular Function

• 5.1 Carboxypeptidase Activity Targets
• 5.2 Catalytic Activity Targets
• 5.3 Cell Adhesion Molecule Activity Targets
• 5.4 Chaperone Activity Targets
• 5.5 Chemokine Activity Targets
• 5.6 Cofactor Binding Targets
• 5.7 Complement Activity Targets
• 5.8 Cytokine Activity Targets
• 5.9 DNA Topoisomerase Activity Targets
• 5.10 Extracellular Matrix Structural Constituent Targets
• 5.11 G-protein Coupled Receptor Activity Targets
• 5.12 Growth Factor Activity Targets
• 5.13 Hormone Activity Targets
• 5.14 Hydrolase Activity Targets
• 5.15 Intracellular Ligand-gated Ion Channel Activity Targets
• 5.16 Metallopeptidase Activity Targets
• 5.17 MHC Class I Receptor Activity Targets
• 5.18 Molecular Function Unknown Targets
• 5.19 Oxidoreductase Activity Targets
• 5.20 Peptide Hormone Targets
• 5.21 Protease Inhibitor Activity Targets
• 5.22 Protein Binding Targets
• 5.23 Receptor Activity Targets
• 5.24 Receptor Binding Targets
• 5.25 Receptor Signaling Complex Scaffold Activity Targets
• 5.26 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
• 5.27 RNA-directed DNA polymerase Activity Targets
• 5.28 Serine-type Peptidase Activity Targets
• 5.29 T Cell Receptor Activity Targets
• 5.30 Translation Regulator Activity Targets
• 5.31 Transmembrane Receptor Activity Targets
• 5.32 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
• 5.33 Transporter Activity Targets
• 5.34 Unclassified Targets

6 Antibody Drugs Targeting Signaling Pathways

• 6.1 Alpha6 Beta4 Integrin Signaling Pathway
  • 6.1.1 Description of Pathway
  • 6.1.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.2 Androgen Receptor Signaling Pathway
  • 6.2.1 Description of Pathway
  • 6.2.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.3 B Cell Receptor Signaling Pathway
  • 6.3.1 Description of Pathway
  • 6.3.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
• 6.4 EGFR1 Signaling Pathway
  • 6.4.1 Description of Pathway
  • 6.4.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.5 IL-2 Signaling Pathway
  • 6.5.1 Description of Pathway
  • 6.5.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
• 6.6 IL-4 Signaling Pathway
  • 6.6.1 Description of Pathway
  • 6.6.2 Antibody Drugs by Target, Developmental Stage and Cancer Type
• 6.7 IL-6 Signaling Pathway
  • 6.7.1 Description of Pathway
  • 6.7.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.8 Kit Receptor Signaling Pathway
  • 6.8.1 Description of Pathway
  • 6.8.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.9 Notch Signaling Pathway
  • 6.9.1 Description of Pathway
  • 6.9.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.10 T Cell Receptor Signaling Pathway
  • 6.10.1 Description of Pathway
  • 6.10.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.11 TGF-beta Receptor Signaling Pathway
  • 6.11.1 Description of Pathway
  • 6.11.2 Antibody Drugs byTarget, Developmental Stage, and Cancer Type
• 6.12 TNF-alpha Signaling Pathway
  • 6.12.1 Description of Pathway
  • 6.12.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type
• 6.13 Wnt Signaling Pathway
  • 6.13.1 Description of Pathway
  • 6.13.2 Antibody Drugs by Target, Developmental Stage, and Cancer Type

7 Antibodies Targeting Cancer Stem Cells

8 Targets of Antibody Conjugates

9 Antibody Drug Targets by Three Major Non Immunological Therapeutic Effects

• 9.1 Anti-Angiogenesis
• 9.2 Apoptosis
• 9.3 Protein Kinase Inhibitors

10 Antibody Targets and Drugs by Cancer Indications

• 10.1 Basal Cell Cancer
• 10.2 Biliary Cancer
• 10.3 Bladder Cancer
• 10.4 Bone Cancer
• 10.5 Brain Cancer
• 10.6 Breast Cancer
• 10.7 Cervical Cancer
• 10.8 Cervical Dysplasia
• 10.9 Colorectal Cancer
• 10.10 Endometrial Cancer
• 10.11 Esophageal Cancer
• 10.12 Fallopian Tube Cancer
• 10.13 Gastrointestinal Cancers
• 10.14 Head and Neck Cancer
• 10.15 Leukemias
• 10.16 Liver Cancer
• 10.17 Lung Cancers
• 10.18 Lymphomas
• 10.19 Melanoma
• 10.20 Mesothelioma
• 10.21 Myelodysplastic syndrome
• 10.22 Myelomas
• 10.23 Nasopharyngeal Cancer
• 10.24 Oesophageal Cancer
• 10.25 Ovarian Cancer
• 10.26 Pancreatic Cancer
• 10.27 Peritoneal Cancer
• 10.28 Prostate Cancer
• 10.29 Renal Cancers
• 10.30 Sarcomas
• 10.31 Thyroid Cancer

11 Expression Profiles of Antibody Drug Targets

• 11.1 Human Tissues and Cancer Tissues
• 11.2 Cancer Lines and Cells

12 Lung cancer: An Introduction

• 12.1 Current Treatment Strategies
• 12.2 Disease Definition
• 12.3 Etiology & Pathophysiology
• 12.4 Prognosis
• 12.5 Epidemiology

13 Progress in Current Lung Cancer Treatment Strategies

• 13.1 Improvements Adding microtubule Inhibitor
• 13.2 Improvement of Disease Related Symptoms in Elderly Patients
• 13.3 Toxicity Profile Favored
• 13.4 A New Formula
• 13.5 Monotherapy?
• 13.6 Failed to Demonstrate a Survival Advantage
• 13.7 Reduction in Mortality Risk

14 Key Drug Strategies in Lung Cancer

• 14.1 Apoptosis
• 14.2 Antiangiogenesis and Antivascular Agents
  • 14.2.1 EGFR and VEGFR as target
  • 14.2.2 Immunotherapy

15 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline

• 15.1 Grade 4 Adverse Events
• 15.2 No New Remarks
• 15.3 No Significant Effect on Overall Survival
• 15.4 Bristol Myers Squibb Entered into an Agreement
• 15.5 Many Uncertainties Remain
• 15.6 Development Terminated
• 15.7 Continuing Enrollment
• 15.8 Apoptotic Inducer
• 15.9 Fully-Human Monoclonal Antibody
• 15.10 Eagerly Awaiting Data
• 15.11 Mutations and Response
• 15.12 Statistically and Clinically Significant Survival Advantage
• 15.13 Anti-Idiotypic Monoclonal Antibody
• 15.14 Shift in the Development Focus
• 15.15 Sensitizer
• 15.16 Treatment in Earlier-Stage Cancer Could be More Effective
• 15.17 Discontinued Radiosensitizer
• 15.18 Improvement in Chemoradiotherapy
• 15.19 Progress on HDAC Inhibitor
• 15.20 Progress Analysis Carboxyamidotriazole
• 15.22 Chemotherapy naïve subjects

16 Etiology and Pathophysiology of Melanoma

17 Current Melanoma Treatment Strategies

• 17.1 An Overview
• 17.2 Cytotoxic Drugs
  • 17.2.1 Dacarbazine
  • 17.2.2 Cisplatin
  • 17.2.3 Carboplatin
  • 17.2.4 Carmustine
  • 17.2.5 Melphalan
  • 17.2.6 Paclitaxel
  • 17.2.7 Tamoxifen
  • 17.2.8 Temozolomide
  • 17.2.9 Vinblastine/Vinorelbine
  • 17.3 Biological treatments
  • 17.3.1 Intron A
  • 17.3.2 Virulizin
  • 17.3.3 Melacine
  • 17.3.4 Alfanative (Multiferon)
  • 17.3.5 Proleukin or (Macrolin)
  • 17.3.6 Enhanzyn
  • 17.3.7 M-VAX
• 17.4 Other
  • 17.4.1 Ceplene Maxamine

18 Key Melanoma Therapy Strategies

• 18.1 Immunotherapy
• 18.2 Anti-angiogenesis
• 18.3 Apoptotic Induction
• 18.4 Gene Therapy

19 Current Melanoma Drug Development: Late Stage Pipeline

• 19.1 Immunotherapy
  • 19.1.1 Oncophage
  • 19.1.2 Canvaxin
  • 19.1.3 GMK
  • 19.1.4 MDX-010
  • 19.1.5 OncoVax
  • 19.1.6 ALLOVECTIN-7
  • 19.1.7 Peginterferon alfa-2b
• 19.2 Anti-angiogenesis
  • 19.2.1 Lenalidomide
• 19.3 Apoptotic Inducers
  • 19.3.1 Genasense
• 19.4 Inhibiting Cell Growth
  • 19.4.1 Temozolomide

20 Current Melanoma Drug Development: Early Stage Pipeline

• 20.1 Immunotherapy
  • 20.1.1 INGN 241
  • 20.1.2 QS-21
  • 20.1.3 Talabostat
  • 20.1.4 SB 249553
  • 20.1.5 GVAX
  • 20.1.6 GV 1001
  • 20.1.7 Dexosome
  • 20.1.8 Uvidem
  • 20.1.9 NY-ESO-1 ISCOMS
  • 20.1.10 NOVOVAC-M1
  • 20.1.11 Oxxon Vaccine
  • 20.1.12 Therion' s Melanoma Vaccine
  • 20.1.13 ImmunoVex trimelan
  • 20.1.14 OncoVEXGM-CSF
  • 20.1.15 Zadaxin
  • 20.1.16 Alvac-Mage1/Mage3
  • 20.1.17 Iboctadekin
  • 20.1.18 ProMune
  • 20.1.19 BAY 504798
  • 20.1.20 EMD 273063
• 20.2 Antiangiogenesis
  • 20.2.1 Sorafenib
  • 20.2.2 Vitaxin
  • 20.2.3 Avastin
  • 20.2.4 PI 88
• 20.3 Apoptotic Inducers
  • 20.3.1 Didemnin B
  • 20.3.2 KOS 953
• 20.4 Small Molecules Inhibiting Cell Growth
  • 20.4.1 Pivanex
  • 20.4.2 Karenitecin
  • 20.4.3 Lomeguatrib
  • 20.4.4 PD 0325901
  • 20.4.5 SB 715992
  • 20.4.6 INO 1001
  • 20.4.7 CP 4055
• 20.5 Other Biological Drugs
  • 20.5.1 AP 12009
  • 20.5.2 Ecromeximab
  • 20.5.3 ILX 651
  • 20.5.4 Kahalalide F
  • 20.5.5 ABX MA1
  • 20.5.6 MJV 101
  • 20.5.7 A Russian Melanoma Vaccine
  • 20.5.8 Elea Vaccine
  • 20.5.9 F 50040

21 Disclaimer

22 Appendix 1: Antibody Targets by Companies

23 Appendix 2. Treatment Guide Lines*

• 23.1 References

24 Appendix 3: Selected Company Profiles

• 24.1 Abgenix
• 24.2 Aphton
• 24.3 AstraZeneca
• 24.4 Bristol-Myers Squibb
• 24.5 Eli Lilly
• 24.6 Genentech
• 24.7 Genta
• 24.8 GlaxoSmithKline
• 24.9 ImClone
• 24.10 ISIS Pharmaceuticals
• 24.11 Ligand Pharmaceuticals
• 24.12 OSI Pharmaceuticals
• 24.13 Pfizer
• 24.14 Pharmacyclics
• 24.15 Sanofi- Aventis
• 24.16 Telik

25 Appendix 4 Progress profiles on approved drugs

• 25.1 Docetaxel
• 25.2 Vinorelbine
• 25.3 Gemcitabine
• 25.4 Paclitaxel
• 25.5 Pemetrexed
• 25.6 Gefitinib
• 25.7 Erlotinib

26 Appendix 4: Treatment Guide Lines Melanoma

27 Drug Index

28 Company Index

3.1 List of Figures

• Figure 1: Antibody Pipeline Maturity by Molecular Function Classes of Targets 1(3)
• Figure 2: Antibody Pipeline Maturity by Molecular Function Classes of Targets 2(3)
• Figure 3: Antibdody Pipeline Maturity by Molecular Function Classes of Targets 3(3)
• Figure 4: Pipeline Maturation of Carboxypeptidase Activity Targets
• Figure 5: Number of Antibody Drugs per Cancer Indication and Carboxypeptidase Activity Target
• Figure 6: Pipeline Maturation of Catalytic Activity Targets
• Figure 7: Number of Antibody Drugs per Cancer Indication and Catalytic Activity Target
• Figure 8: Pipeline Maturation of Cell Adhesion Molecule Activity Targets
• Figure 9: Number of Antibody Drugs per Cancer Indication and Cell Adhesion Molecule Activity Target
• Figure 10: Pipeline Maturation of Chaperone Activity Targets
• Figure 11: Number of Antibody Drugs per Cancer Indication and Chaperone Activity Target
• Figure 12: Pipeline Maturation of Chemokine Activity Targets
• Figure 13: Number of Antibody Drugs per Cancer Indication and Chemokine Activity Target
• Figure 14: Pipeline Maturation of Cofactor Binding Targets
• Figure 15: Number of Antibody Drugs per Cancer Indication and Cofactor Binding Target
• Figure 16: Pipeline Maturation of Complement Activity Targets
• Figure 17: Number of Antibody Drugs per Cancer Indication and Complement Activity Target
• Figure 18: Pipeline Maturation of Cytokine Activity Targets
• Figure 19: Number of Antibody Drugs per Cancer Indication and Cytokine Activity Target
• Figure 20: Pipeline Maturation of DNA Topoisomerase Activity Targets
• Figure 21: Number of Antibody Drugs per Cancer Indication and DNA Topoisomerase Activity Target
• Figure 22: Pipeline Maturation of Extracellular Matrix Structural Constituent Targets
• Figure 23: Number of Antibody Drugs per Cancer Indication and Extracellular Matrix Structural Constituent Target
• Figure 24: Pipeline Maturation of G-protein Coupled Receptor Activity Targets
• Figure 25: Number of Antibody Drugs per Cancer Indication and Extracellular G-protein Coupled Receptor Activity Target
• Figure 26: Pipeline Maturation of Growth Factor Activity Targets
• Figure 27: Number of Antibody Drugs per Cancer Indication and Extracellular Growth Factor Activity Target
• Figure 28: Pipeline Maturation of Hormone Activity Targets
• Figure 29: Number of Antibody Drugs per Cancer Indication and Hormone Activity Target
• Figure 30: Pipeline Maturation of Hydrolase Activity Targets
• Figure 31: Number of Antibody Drugs per Cancer Indication and Hydrolase Activity Target
• Figure 32: Pipeline Maturation of Ligand-gated Ion Channel Activity Targets
• Figure 33: Number of Antibody Drugs per Cancer Indication and Intracellular Ligand-gated Ion Channel Activity Target
• Figure 34: Pipeline Maturation of Metallopeptidase Activity Targets
• Figure 35: Number of Antibody Drugs per Cancer Indication and Intracellular Metallopeptidase Activity Target63
• Figure 36: Pipeline Maturation of MHC Class I Receptor Activity Targets
• Figure 37: Number of Antibody Drugs per Cancer Indication and MHC Class I Receptor Activity Target
• Figure 38: Pipeline Maturation of Molecular Function Unknown Targets
• Figure 39: Number of Antibody Drugs per Cancer Indication and Molecular Function Unknown Target
• Figure 40: Pipeline Maturation of Oxidoreductase Activity Targets
• Figure 41: Number of Antibody Drugs per Cancer Indication and Oxidoreductase Activity Target
• Figure 42: Pipeline Maturation of Peptide Hormone Targets
• Figure 43: Number of Antibody Drugs per Cancer Indication and Peptide Hormone Target
• Figure 44: Pipeline Maturation of Protease inhibitor Activity Targets
• Figure 45: Number of Antibody Drugs per Cancer Indication and Protease Inhibitor Activity Target
• Figure 46: Pipeline Maturationof Protein Binding Targets
• Figure 47: Number of Antibody Drugs per Cancer Indication and Protein Binding Target
• Figure 48: Pipeline Maturation of Receptor Activity Targets 1 (2)
• Figure 49: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 1(2)
• Figure 50: Pipeline Maturation of Receptor Activity Targets 2 (2)
• Figure 51: Number of Antibody Drugs per Cancer Indication and Receptor Activity Target 2(2)
• Figure 52: Pipeline Maturationof Receptor Binding Targets
• Figure 53: Number of Antibody Drugs per Cancer Indication and Receptor Binding Target
• Figure 54: Pipeline Maturation of Receptor Signaling Complex Scaffold Activity Targets
• Figure 55: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Complex Scaffold Activity Target
• Figure 56: Pipeline Maturation of by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets
• Figure 57: Number of Antibody Drugs per Cancer Indication and Receptor Signaling Protein Tyrosine Phosphatase Activity Target
• Figure 58: Pipeline Maturation of RNA-directed DNA polymerase Activity Targets
• Figure 59: Number of Antibody Drugs per Cancer Indication and RNA-directed DNA polymerase Activity Target
• Figure 60: Pipeline Maturation of Serine-type Peptidase Activity Targets
• Figure 61: Number of Antibody Drugs per Cancer Indication and RNA Serine-type Peptidase Activity Target
• Figure 62: Pipeline Maturation of T cell Receptor Activity Targets
• Figure 63: Number of Antibody Drugs per Cancer Indication and T cell Receptor Activity Target
• Figure 64: Pipeline Maturation of Translation Regulator Activity Targets
• Figure 65: Number of Antibody Drugs per Cancer Indication and Translation Regulator Activity Target
• Figure 66: Pipeline Maturation of Transmembrane Receptor Activity Targets
• Figure 67: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Activity Target
• Figure 68: Pipeline Maturation of Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
• Figure 69: Number of Antibody Drugs per Cancer Indication and Transmembrane Receptor Protein Tyrosine Kinase Activity Target
• Figure 70: Pipeline Maturation of Transporter Activity Targets
• Figure 71: Number of Antibody Drugs per Cancer Indication and Transporter Activity Target
• Figure 72: Pipeline Maturation of Unclassified Targets
• Figure 73: Number of Antibody Drugs per Cancer Indication and Unclassified Target
• Figure 74: Antibody Pipeline Comparison of Targeted Signaling Pathways in Oncology
• Figure 75: Pipeline Maturation of Immunoconjugated Antibody Targets
• Figure 76: Number of Immunoconjugated Antibody Drugs per Cancer Indication and Target

3.2 List of Tables

• Table 1: Molecular Functions versus Oncology Antibody Drug Targets
• Table 2: Cancer Antibody Pipeline Listed by Carboxypeptidase Activity Targets
• Table 3: Cancer Antibody Pipeline Listed by Catalytic Activity Targets
• Table 4: Cancer Antibody Pipeline Listed by Cell Adhesion Molecule Activity Targets
• Table 5: Cancer Antibody Pipeline Listed by Chaperone Activity Targets
• Table 6: Cancer Antibody Pipeline Listed by Chemokine Activity Targets
• Table 7: Cancer Antibody Pipeline Listed by Cofactor Binding Targets
• Table 8: Cancer Antibody Pipeline Listed by Complement Activity Targets
• Table 9: Cancer Antibody Pipeline Listed by Cytokine Activity Targets
• Table 10: Cancer Antibody Pipeline Listed by DNA Topoisomerase Activity Targets
• Table 11: Cancer Antibody Pipeline Listed by Extracellular Matrix Structural Constituent Targets
• Table 12: Cancer Antibody Pipeline Listed by G-protein Coupled Receptor Activity Targets
• Table 13: Cancer Antibody Pipeline Listed by Growth Factor Activity Targets
• Table 14: Cancer Antibody Pipeline Listed by Hormone Activity Targets
• Table 15: Cancer Antibody Pipeline Listed by Hydrolase Activity Targets
• Table 16: Cancer Antibody Pipeline Listed by Intracellular Ligand-gated Ion Channel Activity Targets
• Table 17: Cancer Antibody Pipeline Listed by Metallopeptidase Activity Targets
• Table 18: Cancer Antibody Pipeline Listed by MHC Class I Receptor Activity Targets
• Table 19: Cancer Antibody Pipeline Listed by Molecular Function Unknown Targets
• Table 20: Cancer Antibody Pipeline Listed by Oxidoreductase Activity Targets
• Table 21: Cancer Antibody Pipeline Listed by Peptide Hormone Targets
• Table 22: Cancer Antibody Pipeline Listed by Protease inhibitor Activity Targets
• Table 23: Cancer Antibody Pipeline Listed by Protein Binding Targets
• Table 24: Cancer Antibody Pipeline Listed by Receptor Activity Targets
• Table 25: Cancer Antibody Pipeline Listed by Receptor Binding Targets
• Table 26: Cancer Antibody Pipeline Listed by Receptor Signaling Complex Scaffold Activity Targets
• Table 27: Cancer Antibody Pipeline Listed by Receptor Signaling Protein Tyrosine Phosphatase Activity Targets87
• Table 28: Cancer Antibody Pipeline Listed by RNA-directed DNA polymerase Activity Targets
• Table 29: Cancer Antibody Pipeline Listed by Serine-type Peptidase Activity Targets
• Table 30: Cancer Antibody Pipeline Listed by T cell Receptor Activity Targets
• Table 31: Cancer Antibody Pipeline Listed by Translation Regulator Activity Targets
• Table 32: Cancer Antibody Pipeline Listed by Transmembrane Receptor Activity Targets
• Table 33: Cancer Antibody Pipeline Listed by Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
• Table 34: Cancer Antibody Pipeline Listed by Transporter Activity Targets
• Table 35: Cancer Antibody Pipeline Listed by Unclassified Targets
• Table 36: Antibody Drugs Targeting Signaling Pathways
• Table 37: Signaling Pathway Analysis of Oncology Antibody Drug Targets
• Table 38: Targets Linking Antibody Drugs to the Alpha6 Beta4 Integrin Signaling Pathway
• Table 39: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Alpha6 Beta4 Integrin Signaling Pathway
• Table 40: Targets Linking Antibody Drugs to the Androgen Receptor Signaling Pathway
• Table 41: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Androgen Receptor Signaling Pathway
• Table 42: Targets Linking Antibody Drugs to the B Cell Receptor Signaling Pathway
• Table 43: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the B Cell Receptor Signaling Pathway
• Table 44: Targets Linking Antibody Drugs to the EGFR1 Signaling Pathway
• Table 45: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the EGFR1 Signaling Pathway
• Table 46: Targets Linking Antibody Drugs to the IL-2 Signaling Pathway
• Table 47: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-2 Signaling Pathway
• Table 48: Targets Linking Antibody Drugs to the IL-4 Signaling Pathway
• Table 49: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-4 Signaling Pathway
• Table 50: Targets Linking Antibody Drugs to the IL-6 Signaling Pathway
• Table 51: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the IL-6 Signaling Pathway
• Table 52: Targets Linking Antibody Drugs to the Kit Receptor Signaling Pathway
• Table 53: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Kit Receptor Signaling Pathway
• Table 54: Targets Linking Antibody Drugs to the Notch Signaling Pathway
• Table 55: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Notch Signaling Pathway
• Table 56: Targets Linking Antibody Drugs to the T Cell Receptor Signaling Pathway
• Table 57: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the T Cell Receptor Signaling Pathway
• Table 58: Targets Linking Antibody Drugs to the TGF-beta Receptor Signaling Pathway
• Table 59: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TGF-beta Receptor Signaling Pathway
• Table 60: Targets Linking Antibody Drugs to the TNF-alpha Signaling Pathway
• Table 61: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the TNF-alpha Signaling Pathway
• Table 62: Targets Linking Antibody Drugs to the Wnt Signaling Pathway
• Table 63: Antibodies, Listed by Investigator, Developmental Stage, and Cancer Type, Targeting the Wnt Signaling Pathway
• Table 64: Cell Surface Markers of Identified Cancer Stem Cells in Human Tumors
• Table 65: Signaling Pathways Involved in Stem Cell Self-Renewal
• Table 66: Immunoconjugated Antibody Targets According to Molecular Function of Target
• Table 67: Immunoconjugated Antibody Pipeline According to Target
• Table 68: Antibodies in Oncology Reported to Affect Angiogenesis
• Table 69: Antibodies in Oncology Reported to Affect Apoptosis
• Table 70: Antibody Drug Protein Kinase Targets Ranked by Probability of Carrying at Least One Driver Mutation, Conditional on the Gene-Specific Selection Pressures
• Table 71: Antibodies in Oncology Reported to Act as Protein Kinase Inhibitors
• Table 72: Cancer Indicaions by Number of Known Antibody Targets, Number of Antibody Drugs, and Highest Developmental Stage
• Table 73: Antibody Pipeline by Targets in Basal Cell Cancer
• Table 74: Antibody Pipeline by Targets in Biliary Cancer
• Table 75: Antibody Pipeline by Targets in Bladder Cancer
• Table 76: Antibody Pipeline by Targets in Bone Cancer
• Table 77: Antibody Pipeline by Targets in Brain Cancer
• Table 78: Antibody Pipeline by Targets in Breast Cancer
• Table 79: Antibody Pipeline by Targets in Cervical Cancer
• Table 80: Antibody Pipeline by Targets in Cervical Dysplasia
• Table 81: Antibody Pipeline by Targets in Colorectal Cancer
• Table 82: Antibody Pipeline by Targets in Endometrial Cancer
• Table 83: Antibody Pipeline by Targets in Esophageal Cancer
• Table 84: Antibody Pipeline by Targets in Fallopian Tube Cancer
• Table 85: Antibody Pipeline by Targets in Gastrointestinal Cancers
• Table 86: Antibody Pipeline by Targets in Head and Neck Cancer
• Table 87: Antibody Pipeline by Targets in Leukemias
• Table 88: Antibody Pipeline by Targets in Liver Cancer
• Table 89: Antibody Pipeline by Targets in Lung Cancers
• Table 90: Antibody Pipeline by Targets in Lymphomas
• Table 91: Antibody Pipeline by Targets in Melanoma
• Table 92: Antibody Pipeline by Targets in Mesothelioma
• Table 93: Antibody Pipeline by Targets in Myelodysplastic syndrome
• Table 94: Antibody Pipeline by Targets in Myelomas
• Table 95: Antibody Pipeline by Targets in Nasopharyngeal Cancer
• Table 96: Antibody Pipeline by Targets in Oesophageal Cancer
• Table 97: Antibody Pipeline by Targets in Ovarian Cancer
• Table 98: Antibody Pipeline by Targets in Pancreatic Cancer
• Table 99: Antibody Pipeline by Targets in Peritoneal Cancer
• Table 100: Antibody Pipeline by Targets in Prostate Cancer
• Table 101: Antibody Pipeline by Targets in Renal Cancers
• Table 102: Antibody Pipeline by Targets in Sarcomas
• Table 103: Antibody Pipeline by Targets in Thyroid Cancer
• Table 104: Expression Profiles of Antibody Drug Targets in Oncology
• Table 1: Chemotherapeutic drugs for treatment of NSCLC
• Table 2. Near Term Approved Drugs for the Treatment of NSCLC
• Table 3: Chemotherapy Drugs off Patent
• Table 4: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
• Table 5: VTA agents under development
• Table 6: EGFR or VEGFR inhibitors
• Table 7: FMS-like tyrosine kinases and their Synonyms
• Table 8: Fms-related Tyrosine Kinase Targets in Development
• Table 9: Protein Kinase Targets in Clinical Trials for Lung Cancer
• Table 10: Cancer immunotherapy strategies
• Table 11: Recently presented studies Lapatinib
• Table 12: Recently presented studies ZD-6474
• Table 13: Recently presented studies vinflunine
• Table 14: Recently presented studies Panitumumab
• Table 15: Recently presented studies Genasense
• Table 16: Recently presented studies cetuximab
• Table 17: Recently presented studies bevacizumab
• Table 18: Recently presented studies bexarotene
• Table 19: Recently presented studies Xcytrin
• Table 1: Critical Risk Factors for Development of Melanoma
• Table 2: Definition and Description of Stages of Melanoma
• Table 3: Prognosis of the 4 Stages of Malignant Melanoma
• Table 4: Current Cytotoxic Drugs for the Treatment of Melanoma
• Table 5: Progress Profile Dacarbazine
• Table 6: Progress Profile Cisplatin
• Table 7: Progress Profile Carboplatin
• Table 8: Progress Profile Carmustine
• Table 9: Progress Profile Melphalan
• Table 10: Progress Profile Paclitaxel
• Table 11: Progress Profile Tamoxifen
• Table 12: Progress Profile Temozolomide
• Table 13: Progress Profile Vinblastine/Vinorelbine
• Table 14: Progress Profile Interferon alfa-2b
• Table 15: Development Milestones- Virulizin
• Table 16: Development Milestones - Melacine
• Table 17: Development Milestones - Alfanative
• Table 18: Development Milestones - Proleukin
• Table 19: Deployed Strategies for Blocking Angiogenesis
• Table 20: Phase III Randomized Studies of Melanoma Vaccines.
• Table 21: Tumor antigen based vaccines
• Table 22: In vivo Gene Therapy
• Table 23: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
• Table 24: Ex vivo gene therapy loading of antigen presenting cells
• Table 25: Overview of Immunostimulants in Development based on Type
• Table 26: Overview of Immuno-Biologicals
• Table 27: Overview of Gene Therapy Drugs for Immunostimulation
• Table 28: MDX-010' s Collaborative History and Landscape
• Table 29: Anti-angiogenisis Drugs under Development
• Table 30: Overview Apoptopic Inducer Drugs
• Table 31: Overview of Small Molecule Drugs
• Table 32: Selected Regulatory Progress of Sorafenib
• Table 33: Selected Regulatory Progress of Didemin B
• Table 34: Overview of Various Biological Drugs in Development for Melanoma

3.3 List of Boxes

• Box 1: Quick facts on Docetaxel
• Box 2: Scientific Data on Docetaxel
• Box 3: Quick Facts - Vinorelbine
• Box 4: Scientific Data on Vinorelbine
• Box 5: Quick Facts - Gemcitabine
• Box 6: Scientific Data on gemcitabine
• Box 8: Quick Facts - pemetrexed
• Box 7: Scientific Data on Pemetrexed
• Box 9: Quick Facts - Gefitinib
• Box 10: Scientific Data on Gefitinib
• Box 11: Quick Facts - Erlotinib
• Box 1: Quick Facts - Enhanzyn
• Box 2: Quick Facts - M-VAX
• Box 3: M-VAX - Business & Market Bakground
• Box 4: Mechanisms which Tumor Cells use to Evade an Immune Reaction
• Box 5: Introgen' s INGN 241 Shows Vaccine Properties
• Box 6: Quick Facts - Oncophage
• Box 7: Oncophage - Designation and Status
• Box 8: Quick Facts - Canvaxin
• Box 9: Canvaxin - Designation and Status
• Box 10: CancerVax Milestone payment
• Box 11: Quick Facts - GM2-KLH Vaccine
• Box 12: Progenics Reaquires Rights to Vaccine
• Box 13: Completed Melanoma Phase III trials
• Box 14: Quick Facts - MDX-010
• Box 15: Quick Facts -OncoVax
• Box 16: Quick Facts - ALLOVECTIN-7
• Box 17: Quick Facts - Peginterferon alfa-2b
• Box 18: Introgen' s INGN 241 Shows Anti-angiogenesis Properties
• Box 19: Quick Facts - Lenalidomide
• Box 20: Quick Facts - Oblimersen
• Box 21: Quick Facts - Temozomide
• Box 22: Molecular Pathways Underlying the Activity of Temozolomide' s Anti-Cancer Therapy
• Box 23: Regulatory Progress
• Box 24: Quick Facts - INGN 241
• Box 25: Molecular Pathways Underlying Activity of Introgen' s INGN 241 Anti-Cancer Therapy
• Box 26: Quick Facts - QS-21
• Box 27: Quick Facts - Talabostat
• Box 28: Quick Facts - SB 249553
• Box 29: Quick Facts - GVAX
• Box 30: Agreement Japan Tobacco and Cell Genesys
• Box 31: Predicted launch of GVAX
• Box 32: Quick Facts - GV 1001
• Box 33: Quick Facts - Dexosome
• Box 34: Important Milestones and License Fees
• Box 35: Quick Facts - Uvidem
• Box 36: Agreements Between Sanofi-Aventis and IDM
• Box 37: Quick Facts - NY-ESO-1 ISCOMS
• Box 38: NY-ESO-1 and ISCOMATRIX
• Box 39: Quick Facts - NovoVac-M1
• Box 40: Quick Facts - Oxxon vaccine
• Box 41: Quick Facts - Therion' s Melanoma Vaccine
• Box 42: Quick Facts - ImmunoVEX trimelan
• Box 43: Quick Facts - OncoVEX GM-CSF
• Box 44: Quick Facts - ZADAXIN
• Box 45: Developmental History Thymosin alpha1
• Box 46: Quick Facts - Alvac-Mage1/Mage3
• Box 47: Quick Facts - iboctadekin
• Box 48: Quick Facts - PF-3512676
• Box 49: Quick Facts - BAY-504798
• Box 50: Quick Facts - EMD-273063
• Box 51: Quick Facts - Sorefenib
• Box 52: Quick Facts - Vitaxin
• Box 53: Quick Facts . Bevacizumab
• Box 54: Quick Facts - PI88
• Box 55: Quick Facts - Didemnin B
• Box 56: Quick Facts - KOS 953
• Box 57: Quick Facts - Pivanex
• Box 58: Quick Facts - Karenitecin
• Box 59: Company Statement
• Box 60: Quick Facts - Lomeguatrib
• Box 61: Quick Facts - PD 0325901
• Box 62: Quick Facts - SB 715992
• Box 63: Quick Facts - INO 1001
• Box 64: Quick Facts - CP 4055
• Box 65: Quick Facts - AP 12009
• Box 66: Quick Facts - Ecromeximab
• Box 67: Quick Facts - ILX 651
• Box 68: Quick Facts - Kahalalide F
• Box 69: Quick Facts - ABX MA1
• Box 70: Quick Facts - MJV 101
• Box 71: Quick Facts - Russian Melanoma Vaccine
• Box 72: Quick Facts - N-Acetyl-GM3 ganglioside
• Box 73: Quick Facts - F 50040
• Box 74: KpOmpA Technology